CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Eltrombopag

Eltrombopag

Last Updated: March 31, 2014

Result type: Reports

Project Number: SR0377-000

Product Line: Reimbursement Review

Generic Name: Eltrombopag

Brand Name: Revolade

Manufacturer: GlaxoSmithKline

Therapeutic Area: Thrombocytopenia associated with chronic hepatitis c infection

Indications: Thrombocytopenia associated with chronic hepatitis c infection

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: March 18, 2015

Recommendation Type: List with criteria/condition

Eltrombopag

Files